South San Francisco, CA
Summary
This business specializes in AI-powered drug discovery, focusing on developing innovative treatments for significant medical challenges. Utilizing a proprietary multi-omics database derived from human tissue, the company employs machine learning to identify disease causes and create drug candidates. Their first drug targets amyotrophic lateral sclerosis (ALS) and they are also working on treatments for Parkinson's Disease and Frontotemporal Dementia.
Based on content on vergegenomics.com
darmiyan.com
Healthcare technology focused on neurodegenerative disease detection and brain health monitoring.
sygnaturediscovery.com
Nottingham, UK
Pharmaceutical Contract Research Organization (CRO)
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
9.5 years — Since Jul 2015
Web Hosting
Platform
E-Mail Provider
Google GSuite
NAICS Code
541714
SIC 4 Digit Code
8731
SIC 2 Digit Code
87
Industry
1. Biotechnology and Pharmaceuticals
2. Research and Development in Biotechnology (except Nanobiotechnology)
No vendors identified.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2016 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2017 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2019 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
| 2024 |
|
|
|
|
|
|
|
|
|
|
|
|